Prognostic Value of C-Reactive Protein-to-Albumin Ratio in Head and Neck Cancer: A Meta-Analysis

Luan, Chih‐Wei; Yang, Hsin-Yi; Tsai, Yao‐Te; Hsieh, Meng‐Che; Chou, Hsin‐Hsu; Chen, Kuo-Su

doi:10.3390/diagnostics11030403

Cited by 20 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, researchers have used the CRP/Alb ratio to predict the clinical prognosis of patients with cancer. A high CRP/Alb ratio is considered a marker of adverse clinical outcomes in tumors [10,11]. Likewise, in our study, a high CRP/Alb ratio was closely related to disease severity and progression and was an independent risk factor for disease progression in patients with severe COVID-19.…”

Section: Disease Markerssupporting

confidence: 75%

“…Based on these characteristics, clinical researchers speculate that the CRP/Alb ratio, a compound index, is a promising new biomarker in patients with cytokine storm syndrome. Previous studies have shown that CRP/Alb ratio is a promising prognostic biomarker for critically illness [9], cancers [10,11], and Kawasaki disease [12]. Based on current data, CRP/Alb ratio could predict adverse clinical outcomes.…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio

Chen

et al. 2021

Disease Markers

View full text Add to dashboard Cite

Background. Early identification of patients with severe coronavirus disease (COVID-19) at an increased risk of progression may promote more individualized treatment schemes and optimize the use of medical resources. This study is aimed at investigating the utility of the C-reactive protein to albumin (CRP/Alb) ratio for early risk stratification of patients. Methods. We retrospectively reviewed 557 patients with COVID-19 with confirmed outcomes (discharged or deceased) admitted to the West Court of Union Hospital, Wuhan, China, between January 29, 2020 and April 8, 2020. Patients with severe COVID-19 ( n = 465 ) were divided into stable ( n = 409 ) and progressive ( n = 56 ) groups according to whether they progressed to critical illness or death during hospitalization. To predict disease progression, the CRP/Alb ratio was evaluated on admission. Results. The levels of new biomarkers, including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, CRP/Alb ratio, and systemic immune-inflammation index, were higher in patients with progressive disease than in those with stable disease. Correlation analysis showed that the CRP/Alb ratio had the strongest positive correlation with the sequential organ failure assessment score and length of hospital stay in survivors. Multivariate logistic regression analysis showed that percutaneous oxygen saturation (SpO2), D-dimer levels, and the CRP/Alb ratio were risk factors for disease progression. To predict clinical progression, the areas under the receiver operating characteristic curves of Alb, CRP, CRP/Alb ratio, SpO2, and D-dimer were 0.769, 0.838, 0.866, 0.107, and 0.748, respectively. Moreover, patients with a high CRP/Alb ratio (≥1.843) had a markedly higher rate of clinical deterioration ( log − rank p < 0.001 ). A higher CRP/Alb ratio (≥1.843) was also closely associated with higher rates of hospital mortality, ICU admission, invasive mechanical ventilation, and a longer hospital stay. Conclusion. The CRP/Alb ratio can predict the risk of progression to critical disease or death early, providing a promising prognostic biomarker for risk stratification and clinical management of patients with severe COVID-19.

show abstract

Section: Disease Markerssupporting

confidence: 75%

Section: Introductionmentioning

confidence: 97%

Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio

Chen

et al. 2021

Disease Markers

View full text Add to dashboard Cite

show abstract

“… 4 Therefore, a large number of peripheral inflammatory and/or nutritional indexes, such as hemoglobin (HB), platelet (PLT), monocyte (MONO), lymphocyte (LYMPH), neutrophil (NEUT), albumin (ALB), prealbumin (PALB), C-reactive protein (CRP), CRP to ALB ratio (CAR), NEUT to LYMPH ratio (NLR), PLT to LYMPH ratio (PLR), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII), have been reported to be associated with tumor prognosis. 5 - 12 However, nutritional and/or inflammatory status may influenced by various non-cancer-related conditions, which may lead to biased results. Moreover, these peripheral indexes are deficient in some respects, and the results for some indexes are still controversial.…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study

et al. 2022

View full text Add to dashboard Cite

Background Recent studies revealed that various inflammatory and nutritional indexes were associated with prognosis in esophageal cancer (EC). However, these studies only evaluated one or two indexes, and the prognostic value of these indexes individually or in combination is unclear. This study aimed to construct an integrative score based on various inflammatory and nutritional indexes for prognosis in resectable esophageal squamous cell carcinoma (ESCC). Methods A total of 421 consecutive patients were randomly divided into either a training or validation cohort at a ratio of 7:3 for retrospective analysis. Using logic regression analyses, independent risk factors from peripheral blood indexes were screened to construct an integrative score. The associations regarding the integrative score, clinical characteristics, cancer-specific survival (CSS), and overall survival (OS) were analyzed. Results Out of 20 indexes, hemoglobin (HB), C-reactive protein to albumin ratio (CAR), and platelet to lymphocyte ratio (PLR) were independent risk factors based on logical regression analyses. Then, an integrative score with the optimal cut-off value of .67 was established according to the Combination Of HB, CAR, and PLR (COHCP). The area under the curve (AUC) indicated higher predictive ability of COHCP on prognosis than other indicators. Multivariate analyses revealed that COHCP serves as an independent prognostic score. Patients with COHCP low group (≤.67) had better 5-year CSS (57.3% vs 13.5%, P < .001) and OS (51.1% vs 12.3%, P < .001) than those with high group, respectively. Finally, the nomogram based on COHCP was established and validated regarding CSS and OS, which can accurately and effectively predict individual survival in resected ESCC. Conclusion The COHCP was a novel, simple, and useful predictor in resectable ESCC. The COHCP-based nomogram may accurately and effectively predict survival.

show abstract

“…Increased evidence has shown that host immunity and systemic inflammation play an important role in cancer angiogenesis and progression, although the exact pathogenesis is not thoroughly understood 5 , 6 . Accumulated studies have shown that many inflammation-based scores, including the neutrophil-to-lymphocyte ratio, Glasgow prognostic score, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein to albumin ratio, are associated with cancer survival and prognosis 7 , 8 . Identification of precise and available prognostic indicators may optimize the management of patients suffering from HNC.…”

Section: Introductionmentioning

confidence: 99%

Pretreatment prognostic nutritional index as a prognostic marker in head and neck cancer: a systematic review and meta-analysis

Luan

Tsai

Yang

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

The predictive value of the pretreatment prognostic nutritional index (PNI) for head and neck cancer (HNC) remains controversial. We conducted a meta-analysis to assess the predictive value of PNI in HNC patients. A systematic search through internet databases including PubMed, Embase, and Cochrane Library for qualified studies estimating the association of PNI with HNC patient survival was performed. Overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), disease-free survival (DFS) and distant metastasis-free survival (DMFS) data were collected and evaluated. A random-effects model was used to calculate the pooled hazard ratios (pHRs) and corresponding 95% confidence intervals (CIs). A total of 7815 HNC patients from 14 eligible studies were involved. Pooled analysis showed that low pretreatment PNI was correlated with poor OS (pHR: 1.93, 95% CI 1.62–2.30, p < 0.001), PFS (pHR: 1.51, 95% CI 1.19–1.92, p = 0.008), DSS (pHR: 1.98, 95% CI 1.12–3.50, p < 0.001), DFS (pHR: 2.20, 95% CI 1.66–2.91, p < 0.001) and DMFS (pHR: 2.04, 95% CI 1.74–2.38, p < 0.001). Furthermore, low pretreatment PNI was correlated with poor OS despite variations in the cancer site, sample size, PNI cut-off value, analysis method (multivariate analysis or univariate analysis) and treatment modality in subgroup analysis. Elevated pretreatment PNI is correlated with a superior prognosis in HNC patients and could be used as a biomarker in clinical practice for prognosis prediction and treatment stratification.

show abstract

Prognostic Value of C-Reactive Protein-to-Albumin Ratio in Head and Neck Cancer: A Meta-Analysis

Cited by 20 publications

References 38 publications

Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio

Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio

Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study

Pretreatment prognostic nutritional index as a prognostic marker in head and neck cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About